Graves’ disease after exposure to the SARS-CoV-2 vaccine: a case report and review of the literature

Background Autoimmune/inflammatory syndrome induced by adjuvants (ASIA) is characterized by immune system dysregulation after exposure to adjuvants, such as aluminum.

Although cases of autoimmune thyroid diseases caused by ASIA have been reported, Graves' disease is one of the rarer diseases.

There are some reports that vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) cause ASIA.

Here, we describe a case of Graves’ disease following SARS-CoV-2 vaccination and a review of the literature.

Case presentation A 41-year-old woman was admitted to our hospital because of palpitations and fatigue.

Two weeks after receiving the second SARS-CoV-2 vaccine (BNT162b2, Coronavirus Modified Uridine messenger RNA (mRNA) Vaccine, Pfizer), she developed fatigue and gradually worsened.

On admission, she exhibited thyrotoxicosis (thyroid-stimulating hormone (TSH) < 0.01 mIU/L (0.08–0.54), free triiodothyronine (FT3) 33.2 pmol/L (3.8–6.3), and free thyroxine (FT4) 72.1 pmol/L (11.6–19.3)) and palpitations associated with atrial fibrillation.

TSH receptor antibody (TRAb) was positive (TRAb 5.0 IU/L (< 2.0)), and ^99mTc scintigraphy showed diffuse uptake in the thyroid gland, suggesting that the thyrotoxicosis in this case was caused by Graves’ disease.

Thiamazole was prescribed to correct her condition, and soon after this treatment was initiated, her symptoms and thyroid hormone levels were significantly reduced.

Conclusions This case report reinforces the potential correlation between ASIA affecting the thyroid and SARS-CoV-2 mRNA vaccines.

The clinical course suggests that it is essential to consider the possibility of developing ASIA, such as Graves' disease, after exposure to the SARS-CoV-2 vaccine.